However, from a medicinal chemistry perspective, the compound STL427944 has metabolic liabilities, to overcome these issues; we did structural modifications by applying several paths of SAR optimization and verified the potency, among the newly designed STL427944 analogues, STL001 (Fig. 1A) showed up to a 50-fold estimated increase in potency as FOXM1 inhibitor in AML [37]. Here, FOXM1 is linked to acute myeloid leukemia.